title: The RGS2 (-391, C>G) genetic variation correlates to antihypertensive drug responses in Chinese patients with essential hypertension.
abstract: OBJECTIVE
  Regulators of G-protein signaling protein 2 (RGS2) play an irreplaceable role in the control of normal blood pressure (BP). One RGS2 (-391, C>G) genetic variation markedly changes its mRNA expression levels. This study explored the relationship between this genetic variation and the responses to antihypertensive drugs in Chinese patients with essential hypertension.
  
  
  METHODS
  Genetic variations of RGS2 were successfully identified in 367 specimens using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays. All patients were treated with conventional doses of antihypertensives after a 2-week run-in period and followed-up according to our protocol. A general linear model multivariate analysis of variance (ANOVA) was used for the data analysis.
  
  
  RESULTS
  A significant difference in the mean systolic BP change was observed between RGS2 (-391, C>G) CC/CG (n = 82) and GG (n = 38) genotype carriers (-13.6 vs. -19.9 mmHg, P = 0.043) who were treated with candesartan, irbesartan or imidapril at the end of 6 weeks. In addition, the patients' BP responses to α,β-adrenergic receptor blockers exhibited an age-specific association with the RGS2 (-391, C>G) genetic variation at the end of 4 weeks.
  
  
  CONCLUSIONS
  The RGS2 (-391, C>G) genetic polymorphism may serve as a biomarker to predict a patient's response to antihypertensive drug therapy, but future studies need to confirm this.
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Fazhong
authors: F
authors: He
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Jianquan
authors: J
authors: Luo
authors: Second uropoiesis surgical department in Han Dan Central Hospital, Handan, P.R.C.
authors: Zhitao
authors: Z
authors: Zhang
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Zhiying
authors: Z
authors: Luo
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Lan
authors: L
authors: Fan
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Yijing
authors: Y
authors: He
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Jiagen
authors: J
authors: Wen
authors: Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
authors: Dingilang
authors: D
authors: Zhu
authors: Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
authors: Jinping
authors: J
authors: Gao
authors: Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
authors: Yan
authors: Y
authors: Wang
authors: Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
authors: Yuesheng
authors: Y
authors: Qian
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Honghao
authors: H
authors: Zhou
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Xiaoping
authors: X
authors: Chen
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R.C; Institute of Clinical Pharmacology, Central South University, Changsha, P.R.C; Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R.C.
authors: Wei
authors: W
authors: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D044466:Asian People; D002681:China; D000075222:Essential Hypertension; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D012150:Polymorphism, Restriction Fragment Length; D020710:RGS Proteins / Q000235:genetics*
chemical_list: D000959:Antihypertensive Agents; D020710:RGS Proteins; C087182:RGS2 protein, human